Search | Clinical Trials Finder

Conditions: Hypercholesterolemia
Interventions: Lapaquistat acetate and current lipid-lowering treatment, Current lipid-lowering treatment; Drug
Lead sponsor: Takeda; Industry
Eligibility: 8 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: Cincinnati, Ohio • Columbus, Ohio

Conditions: Healthy
Interventions: PER977, Placebo, enoxaparin; Drug
Lead sponsor: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy Volunteers
Interventions: REGN1033(SAR391786), Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 2
States / cities: Honolulu, Hawaii • Evansville, Indiana

Conditions: Alzheimer's Disease
Interventions: Longeveron Mesenchymal Stem Cells, Placebo; Biological
Lead sponsor: Longeveron Inc.; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 3
States / cities: Delray Beach, Florida • Miami, Florida

Conditions: Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus, Type 1 Diabetes in Adolescence, Type 1 Diabetes in Children, Type 1 Diabetes (Juvenile Onset), Type 1 Diabetes, Type 1 Diabetes Patients, Type 1 Diabetes Mellitis
Interventions: CNP-103, Placebo; Drug
Lead sponsor: COUR Pharmaceutical Development Company, Inc.; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 45
States / cities: Tucson, Arizona • Newport Beach, California • San Diego, California + 35 more

Conditions: Cognitive Dysfunction, Schizophrenia
Interventions: KYN-5356, placebo; Drug
Lead sponsor: Kynexis B.V.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Glendale, California

Conditions: Covid19, Novel Coronavirus Pneumonia, Acute Respiratory Distress Syndrome
Interventions: MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8), MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8), MSC-exosomes delivered intravenously every other day (8:8:8); Drug
Lead sponsor: AVEM HealthCare; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Panorama City, California

Conditions: Non-Small Cell Lung Cancer
Interventions: Livmoniplimab, Budigalimab, Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 840 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 19
States / cities: La Jolla, California • Pembroke Pines, Florida • Winter Haven, Florida + 16 more

Conditions: Geographic Atrophy, Age-Related Macular Degeneration
Interventions: Emixustat HCl Tablet, Placebo Tablet; Drug · Other
Lead sponsor: Kubota Vision Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Cystic Fibrosis
Interventions: CB-280, Placebos; Drug
Lead sponsor: Calithera Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 17
States / cities: Little Rock, Arkansas • Long Beach, California • Gainesville, Florida + 14 more

Conditions: Healthy Subjects
Interventions: PF-06882961, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Postbariatric Hypoglycemia
Interventions: Mizagliflozin, Placebo; Drug
Lead sponsor: Vogenx, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Palo Alto, California • Aurora, Colorado

Conditions: Healthy
Interventions: ACT-1004-1239, Placebo, ACT-1004-1239 (Food-effect subpart), Placebo (Food-effect subpart); Drug · Other
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Shigellosis
Interventions: Vaccine: 2.6±0.8 x 10^8 vp/mL, 1 dose, Vaccine: 2.6±0.8 x 10^9 vp/mL, 3 doses, Vaccine: 2.6±0.8 x 10^10 vp/mL, 3 doses, Vaccine: 2.6±0.8 x 10^11 vp/mL, 3 doses, Placebo: 1-3 doses; Biological
Lead sponsor: PATH; Other
Eligibility: 18 Years to 45 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Influenza
Interventions: Placebo for VNT-101, VNT-101; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 59 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Zika Virus
Interventions: Single dose of rZIKV/D4Δ30-713 (10^3 PFU) via subcutaneous injection (0.5ml), Single dose of placebo via subcutaneous injection (0.5ml)., Single dose of rZIKV/D4Δ30-713 (10^4 PFU) via subcutaneous injection (0.5ml); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Baltimore, Maryland • Burlington, Vermont

Conditions: HIV -1 Infection
Interventions: Live Biotherapeutic Product L. jensenii 1153-1666, Placebo; Drug
Lead sponsor: Craig Cohen, MD, MPH; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Ulcerative Colitis
Interventions: Filgotinib, PTM filgotinib; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 61
States / cities: Dothan, Alabama • Scottsdale, Arizona • Long Beach, California + 53 more

Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Interventions: MNKD-201(Nintedanib DPI), Placebo; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 9
States / cities: Fresno, California • Palm Springs, California • Doral, Florida + 5 more

Conditions: Heart Failure
Interventions: CXL-1020, Placebo for CXL-1020 Cohort 1, Placebo for CXL-1020 Cohort 2, CXL-1020 Dose for Echo Cohort A, CXL-1020 Doses for Echo Cohort B; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Tustin, California

Conditions: Graves Disease
Interventions: MER511 (IV), Placebo comparator (IV), MER511 (SC), Placebo comparator (SC), MER511 (SC) for MAD, Placebo comparator (SC) for MAD; Biological
Lead sponsor: Merida Biosciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 11
States / cities: Torrance, California • Hollywood, Florida • Miami, Florida + 8 more

Conditions: Primary Sjögren's Syndrome
Interventions: CFZ533 active - Cohort 1, CFZ533 placebo- Cohort 1, CFZ533 active - Cohort 2, CFZ533 placebo - Cohort 2, CFZ533 active - Cohort 3; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 3
States / cities: Boston, Massachusetts • Mineola, New York • Duncansville, Pennsylvania

Conditions: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: LY2228820, Carboplatin, Placebo, Gemcitabine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 19
States / cities: Phoenix, Arizona • Tucson, Arizona • Sarasota, Florida + 15 more

Conditions: Alzheimer's Disease
Interventions: BIIB037, Placebo; Drug · Other
Lead sponsor: Biogen; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Delray Beach, Florida • Orlando, Florida • Beachwood, Ohio

Search by objective public record fields.

Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol Levels in Subjects With Homozygous Familial Hypercholesterolemia

PK and PD of Single, Escalating Doses of PER977 Following Enoxaparin

A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786)

Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease

CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KYN-5356 in Healthy Subjects Aged 18 to 55 Years

The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis

First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects

Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ACT-1004-1239 in Healthy Male Subjects

Safety Study of Inactivated Shigella Whole Cell Vaccine in Adults

First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics

Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults

Safety Study of MucoCept-CVN

Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis

Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure

NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease

Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome

A Study LY2228820 for Recurrent Ovarian Cancer

Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease